RESEARCH PAPER
Prevalence and risk factors of hypertension in HIV-positive adults on antiretroviral therapy in Ondo State, Nigeria
More details
Hide details
1
Department of Community Medicine, College of Medicine, University of Ibadan, Ibadan, Nigeria
2
Department of Epidemiology and Medical Statistics, College of Medicine, University of Ibadan, Ibadan, Nigeria
Submission date: 2019-07-12
Final revision date: 2019-11-07
Acceptance date: 2020-02-04
Publication date: 2020-10-09
HIV & AIDS Review 2020;19(3):199-205
KEYWORDS
TOPICS
ABSTRACT
Introduction:
The occurrence of hypertension in people living with human immunodeficiency virus/acquired immunodeficiency syndrome (PLWHA) on antiretroviral therapy (ART) is increasing. In Nigeria, where the national human immunodeficiency virus (HIV) prevalence is 1.4%, an estimated 700,000 PLWHA are on ART. We investigated the prevalence of hypertension and associated factors among adults on ART in Owo, Ondo State.
Material and methods:
A retrospective study with 300 PLWHA on ART in Federal Medical Centre, Owo, was conducted. Hypertension was defined as systolic blood pressure (SBP) ≥ 140 mm Hg and/or diastolic blood pressure (DBP) ≥ 90 mm Hg. Descriptive statistics were performed. Chi-square tests were used to identify associations between sociodemographic/clinical parameters and hypertension. Odds ratio and adjusted odds ratio were used to examine risk factors associated with hypertension.
Results:
The mean age of PLWHA was 38.3 years (SD, 10.4) and 33.7% were males. Median duration on ART was 6 years (range, 0.5-15). The prevalence of hypertension was 20.3%, with 25.7% in males and 17.5% among females. The prevalence of hypertension before commencing ART was 14.7% and 20.3% after ART was commenced (p = 0.043). Mean SBP was 110 ± 16 mm Hg before ART use and 118 ± 18 after utilization of ART (p < 0.001). Hypertension before commencing ART was associated with age of 38 years and above (OR: 2.7; 95% CI: 1.3-6.8). Amongst PLWHA, hypertension after commencing treatment was associated with being previously hypertensive (AOR: 9.2; 95% CI: 4.5-18.6).
Conclusions:
HIV treatment programs should include screening and management of hypertension. Screening and assessment of risk factors were directed at PLWHA diagnosed with hypertension before commencing ART, while routine check of blood pressure was evaluated at subsequent visits.
REFERENCES (27)
1.
Mannheimer S, Matts J, Telzak E, et al. Quality of life in HIV-infected individuals receiving antiretroviral therapy is related to adherence. AIDS Care 2005; 17: 10-22.
2.
Amberbir A, Woldemichael K, Getachew S, Girma B, Deribe K. Predictors of adherence to antiretroviral therapy among HIV-infected persons: a prospective study in Southwest Ethiopia. BMC Public Health 2008; 30: 265.
4.
Ichiho HM, Demei Y, Kuartei S, Aitaoto N. An assessment of non-communicable diseases, diabetes, and related risk factors in the Republic of Palau: a systems perspective. Hawaii J Med Public Health 2013; 72 (5 Suppl 1): 98-105.
5.
Venkat Narayan KM, Miotti PG, Anand NP, et al. HIV and noncommunicable disease comorbidities in the era of antiretroviral therapy: a vital agenda for research in low- and middle-income country settings. J Acquir Immune Defic Syndr 2014; 67: S2-S7.
6.
Magee MJ, Narayan KM. Global confluence of infectious and non-communicable diseases – the case of type 2 diabetes. Prev Med 2013; 57: 149-151.
7.
Geneau R, Hallen G. Toward a systemic research agenda for addressing the joint epidemics of HIV/AIDS and noncommunicable diseases. AIDS 2012; 26 (Suppl 1): S7-S10.
8.
Lim S, Vos T, Flaxman A, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2224-2260.
9.
Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-2572.
10.
Ilesanmi OS, Ige OK, Adebiyi AO. The managed hypertensive: the costs of blood pressure control in a Nigerian town. Pan Afr Med J 2012; 12: 96.
11.
Lee HJ, Jang SI, Park EC. Effect of adherence to antihypertensive medication on stroke incidence in patients with hypertension: a population-based retrospective cohort study. BMJ Open 2017; 7: e014486-e014486.
12.
IBM SPSS Statistics for Windows: Version 21.0. IBM Corp. Released 2012. Armonk, NY: IBM Corp.
13.
Ogunmola JO, Oladosu OY, Olamoyegun AM. Association of hypertension and obesity with HIV and antiretroviral therapy in a rural tertiary health center in Nigeria: a cross-sectional cohort study. Vasc Health Risk Manag 2014; 10: 129-137.
14.
Malaza A, Mossong J, Bärnighausen T, Newell ML. Hypertension and obesity in adults living in a high HIV prevalence rural area in South Africa. PLoS One 2012; 7: e47761.
15.
Jerico C, Knobel H, Montero M, et al. Hypertension in HIV-infected patients: prevalence and related factors. Am J Hypertens 2005; 18: 1396-1401.
16.
Dimala CA, Atashili J, Mbuagbaw JC, Wilfred A, Monekosso GL. Prevalence of hypertension in HIV/AIDS patients on highly active antiretroviral therapy (HAART) compared with HAART-naïve patients at the Limbe Regional Hospital, Cameroon. PLoS One 2016; 11: e0148100.
17.
Seaberg EC, Munoz A, Lu M, et al. Association between highly active antiretroviral therapy and hypertension in a large cohort of men followed from 1984 to 2003. AIDS 2005; 19: 953-960.
18.
Okello S, Kanyesigye M, Muyindike WR, et al. Incidence and predictors of hypertension in adults with HIV-initiating antiretroviral therapy in south-western Uganda. J Hypertens 2015; 33: 2039-2045.
19.
Medina-Torne S, Ganesan A, Barahona I, Crum-Cianflone NF. Hypertension is common among HIV-infected persons, but not associated with HAART. J Int Assoc Physicians AIDS Care (Chic) 2012; 11: 20-25.
20.
Muhammad S, Sani MU, Okeahialam BN. Cardiovascular disease risk factors among HIV-infected Nigerians receiving highly active antiretroviral therapy. Niger Med J 2013; 54: 185-190.
21.
Crane HM, Van Rompaey SE, Kitahata MM. Antiretroviral medications associated with elevated blood pressure among patients receiving highly active antiretroviral therapy. AIDS 2006; 20: 1019-1026.
22.
Friis-Møller N, Weber R, Reiss P, et al. Cardiovascular disease risk factors in HIV patients – association with antiretroviral therapy. Results from the DAD study. AIDS 2003; 17: 1179-1193.
23.
Bergersen BM, Sandvik L, Dunlop O, Birkeland K, Bruun JN. Prevalence of hypertension in HIV-positive patients on highly active retroviral therapy (HAART) compared with HAART-naive and HIV-negative controls: results from a Norwegian study of 721 patients. Eur J Clin Microbiol Infect Dis 2003; 22: 731-736.
24.
Kotwani P, Kwarisiima D, Clark TD, et al. Epidemiology and awareness of hypertension in a rural Ugandan community: a cross-sectional study. BMC Public Health 2013; 13: 1151-1151.
25.
Bloomfield GS, Hogan JW, Keter A, et al. Hypertension and obesity as cardiovascular risk factors among HIV seropositive patients in Western Kenya. PLoS One 2011; 6: e22288.
26.
Chow FC, Regan S, Feske S, Meigs JB, Grinspoon SK, Triant VA. Comparison of ischemic stroke incidence in HIV-infected and non-HIV-infected patients in a U.S. Health Care System. J Acquir Immune Defic Syndr (1999) 2012; 60: 351-358.
27.
Justice A, Falutz J. Aging and HIV: an evolving understanding. Curr Opin HIV AIDS 2014; 9: 291-293.